|
|
| Back to Press Releases |
Tuesday, August 07, 2007
Intellect Neurosciences, Inc. CEO to Be Interviewed By Market News FirstIntellect Neurosciences, Inc. CEO to Be Interviewed By Market News First, MN1.com
NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS - News), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that Dr. Daniel Chain, CEO and Chairman, will be interviewed live on August 8, 2007 at 11:00 AM ET on Market News First. Dr. Chain will discuss recent developments within the Company.
Shareholders and interested parties may go to www.MN1.com and activate the free player enabling them to listen to management's review of operations, discussion of future prospects and comments on recent news. This live broadcast is available to anyone at any computer connected to the internet with no subscription necessary.
About MN1.com
Market News First is the only online destination that brings real microcap news to investors and features live interaction with companies from the Bulletin Board, Pink Sheets, and Amex. Featuring Live Press Conferences, All- Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items, and "The MicroBlog", MN1.com gives microcap investors the information source necessary to trade in the markets. MN1.com boasts being the largest true news company reporting on microcap traded stocks.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the toxic accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are over 24 million people suffering from Alzheimer's disease in the major markets worldwide with the number projected to increase to 80 million by 2040 as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective disease modifying drugs.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease where no such treatment exists. With the application of novel technology platforms, Intellect Neurosciences has brought a new cutting edge science in the treatment of Alzheimer's disease. Most advanced in the Company's product pipeline is OXIGON(TM) which has been patented in Europe, US and elsewhere for use in treatment of multiple disease indications and disorders including prevention and treatment of Alzheimer's disease. The Company successfully completed Phase I clinical trials for OXIGON(TM) in elderly healthy volunteers. Data from a multiple dose Phase Ib clinical trial, conducted in The Netherlands is expected to be available shortly.
The Company also has broad proprietary immunotherapy platforms with patented drug candidates for both passive and active immunization against Alzheimer's disease. Its pioneering activities in the field have placed it at the forefront of the attack against this devastating disease. Intellect's patent estate contains issued and pending claims in Europe, Japan, the US and other major territories, providing a formidable strategic advantage.
For additional information, please visit http://www.intellectns.com
For further information contact:
Elliot Maza
President & Chief Financial Officer
7 West 18th Street, 9th Floor
New York, NY 10011, USA
Tel: 212-448-9300
|
 |
|
